Exosome injections to improve atrophic facial scars
Official title: Evaluation of Intralesional Exosomes Versus Intralesional Saline in The Treatment of Atrophic Scars: A Randomized Controlled Trial
Run by Zagazig University · NCT07569666 · Data updated 2026-11-12
This trial will test whether injecting exosomes into atrophic facial scars improves their appearance and texture compared with saline injections in adults with multiple facial scars.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 12 (estimated) |
| Sponsor | Zagazig University Government |
| Locations | 1 site (Zagazig, Zagazig) |
| Status | Recruiting |
| Started | June 15, 2025 |
| Main results expected | November 2026 |
| Study ends | February 2027 |
| Registry record updated | May 6, 2026 |
| Trial ID | NCT07569666 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 with multiple atrophic facial scars who can attend Zagazig University Hospitals and are willing to provide informed consent.
✕Probably not a fit
Patients with only one scar, active infection at the scar site, pregnancy, known hypersensitivity to components, or unrealistic expectations may not benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with multiple atrophic scars on one or both sides of the face will be randomly assigned to receive intralesional exosome injections or saline injections as a control, with both patients and evaluators blinded to allocation. Treatments will be given at Zagazig University Hospitals and outcomes will include scar appearance, texture, and safety measures. Participants must be over 18, willing to give informed consent, and free of infection or hypersensitivity at the treatment site. Pregnant people and those with only a single scar or unrealistic expectations are excluded.
Why it matters
Potential benefit: If successful, the treatment could meaningfully improve the look and feel of atrophic scars and boost patient confidence.
How similar studies have gone: Early laboratory and small clinical studies suggest exosomes may aid skin repair, but well-controlled clinical evidence for scar improvement is still limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Age \>18 years * Either gender * Scars of any duration * Multiple scars at one side or both sides of the face. * Patients are willing to sign written informed consent statements before beginning treatment. Exclusion Criteria: * Pregnant females. * Patients with one scar. * Hypersensitivity to any of the used treatments. * Patient with infection at the site of the scar. * Patients with unrealistic expectations. * Patient refusing to sign on the consent.
Where it's running
-
Zagazig University Hospitals
Zagazig, Zagazig, Egypt Recruiting
Study contacts
- Study coordinator: mona Elradi
- Email: monaelradi@medicine.zu.edu.eg
- Phone: +201067070550
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Long-term follow-up after TRTP-101 treatment for scar
This study checks in with people who previously received TRTP-101 to see if the treatment remains safe and helps with atrophic scar over several years.
-
Safety and potential improvement of autologous fat-derived stem cells for adult facial atrophic scars
This study tests whether a single treatment with TRTP-101, made from the patient’s own fat-derived stem cells, is safe and may improve facial acne-related atrophic scars in adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.